The oversubscribed round brings total funding to approximately $12.4 million since inception
UK-based biotechnology company Resurrect Bio has announced the final close of its Series A funding round at $10.3 million, exceeding its original target and underscoring strong investor confidence in next-generation crop protection technologies.
The round was led by Corteva through its Corteva Catalyst platform, with participation from Calculus Capital, Pymwymic, UKI2S (managed by Future Planet Capital), SynBioVen, and AgFunder. The final close brings the company’s total capital raised since inception to approximately $12.4 million.
The oversubscription follows growing momentum in agricultural biotechnology focused on durable, gene-based disease resistance and comes shortly after a joint development agreement with Corteva announced in March 2026 to advance disease resistance traits in corn.
Resurrect Bio is developing an integrated biotechnology platform designed to accelerate the discovery and deployment of crop disease resistance traits through a combination of computational biology, functional screening, and gene reactivation approaches.
At the center of its technology stack is the FloraFold® AI in-silico discovery platform, which models plant–pathogen protein interactions to identify potential resistance pathways. This is complemented by a high-throughput functional biology system that validates predicted interactions at scale, alongside a proprietary “Resurrection” platform aimed at reactivating dormant or cryptic resistance mechanisms already present in elite crop germplasm.
Together, these systems are intended to significantly shorten the timeline between discovery and field deployment of disease-resistant traits, addressing one of the key bottlenecks in traditional crop breeding and trait development.
The newly secured capital will be used to expand research and development operations, scale computational and biological infrastructure, and deepen collaboration with seed companies and plant breeders through joint development agreements.
Chief Executive Officer Cian Duggan said the financing reflects growing conviction in scalable, AI-enabled approaches to agricultural resilience.
“We’re proud to have closed this round with such a distinguished and strategically aligned group of partners,” he said. “The strength of this raise reflects growing conviction in what we’re building: a scalable, AI-driven platform for resurrecting disease resistance in the world’s most important crops.”
He added that the company is actively seeking additional partnerships to accelerate commercial deployment of durable resistance traits across major crop systems.
Investor Elizabeth Klein-Edmonds of Calculus Capital highlighted the persistent global challenge of crop disease and the potential of gene-based solutions to reduce reliance on chemical crop protection while improving yields and farm resilience.
The investment signals continued momentum in agricultural biotechnology, particularly in platforms combining artificial intelligence, gene editing, and advanced plant science to address systemic threats to global food production.
With fresh capital in place, Resurrect Bio is positioning itself at the intersection of computational biology and agricultural innovation, aiming to bring faster, more durable disease resistance solutions to global seed pipelines.
